Compare Stryker Corporation (SYK) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stryker Corporation vs Veritone Inc — how do they compare? Stryker Corporation trades at $277.44 (market cap $105.63B), while Veritone Inc trades at $0.87 (market cap $85.83M). The key difference: Stryker Corporation is far larger — about 1230.7× Veritone Inc's market cap, and Stryker Corporation pays a 1.28% dividend while Veritone Inc pays none. Which is the better fit depends on your goals.
| SYK | VERI | |
|---|---|---|
Market Cap | $105.63B | $85.83M |
Sector | Technology | Technology |
52-Week High | $388.79 | $8.39 |
52-Week Low | $275.39 | $0.79 |
Enterprise Value | $117.10B | $121.22M |
Dividend Yield | 1.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stryker (SYK) is trading at $276.43, down 8.81% over 24 hours, with a bearish technical signal from moving averages but bullish oscillators. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Strong fundamentals include a net income margin of 14.43% and ROE of 16.51%, though valuation ratios like a P/E of 28.65 are elevated. Recent news includes a securities fraud investigation announcement and the launch of an FDA-cleared surgical app for Apple Vision Pro.
The outlook for SYK is supported by solid profitability and growth initiatives like acquisitions and product launches, but near-term risks include the fraud investigation and competitive pressures. Analyst consensus is strongly bullish with a $376 price target, suggesting significant upside potential if the company navigates current challenges successfully.
Veritone (VERI) trades at $0.9155, up 0.99% on the day, amid a bearish technical signal with mixed oscillators. The company reported Q2 2026 revenue of $24.3 million, up 20% sequentially, but continues to post significant losses, with a net income margin of -117.54% in 2025. Recent news highlights a securities class action investigation announced by Kaskela Law on August 20, 2026, adding legal overhangs to operational challenges.
The outlook remains challenged by persistent unprofitability and negative cash flow from operations, offset by a balanced analyst consensus of 46% buy and 46% hold ratings. Key risks include ongoing legal scrutiny, high operating costs, and the need to achieve sustainable profitability to support the stock's valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
